JP2002530354A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002530354A5 JP2002530354A5 JP2000583562A JP2000583562A JP2002530354A5 JP 2002530354 A5 JP2002530354 A5 JP 2002530354A5 JP 2000583562 A JP2000583562 A JP 2000583562A JP 2000583562 A JP2000583562 A JP 2000583562A JP 2002530354 A5 JP2002530354 A5 JP 2002530354A5
- Authority
- JP
- Japan
- Prior art keywords
- monoclonal antibody
- antibody specific
- patients
- transplantation
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 12
- 239000003814 drug Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000003018 immunosuppressive agent Substances 0.000 description 8
- 238000002054 transplantation Methods 0.000 description 7
- 206010052779 Transplant rejections Diseases 0.000 description 6
- 229960004669 basiliximab Drugs 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 4
- 108010036949 Cyclosporine Proteins 0.000 description 4
- 230000001506 immunosuppresive effect Effects 0.000 description 4
- 229960003444 immunosuppressant agent Drugs 0.000 description 4
- 230000001861 immunosuppressant effect Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 229940122739 Calcineurin inhibitor Drugs 0.000 description 3
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 description 3
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 description 3
- 206010062016 Immunosuppression Diseases 0.000 description 3
- 229940046731 calcineurin inhibitors Drugs 0.000 description 3
- 229940125721 immunosuppressive agent Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940124589 immunosuppressive drug Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229940063121 neoral Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- 102000004631 Calcineurin Human genes 0.000 description 1
- 108010042955 Calcineurin Proteins 0.000 description 1
- 208000009693 Gingival Hyperplasia Diseases 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 229940124622 immune-modulator drug Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000011273 social behavior Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9825632.4A GB9825632D0 (en) | 1998-11-23 | 1998-11-23 | Organic compounds |
| GB9825632.4 | 1998-11-23 | ||
| PCT/EP1999/008988 WO2000030679A1 (en) | 1998-11-23 | 1999-11-22 | Cd25 binding molecules for use in the treatment of manifestations of rejection in transplantation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002530354A JP2002530354A (ja) | 2002-09-17 |
| JP2002530354A5 true JP2002530354A5 (cg-RX-API-DMAC7.html) | 2007-01-11 |
Family
ID=10842889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000583562A Pending JP2002530354A (ja) | 1998-11-23 | 1999-11-22 | 移植の拒絶反応の出現の処置に使用するためのｃｄ２５結合分子 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20010041179A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1131098A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2002530354A (cg-RX-API-DMAC7.html) |
| AU (1) | AU1384600A (cg-RX-API-DMAC7.html) |
| GB (1) | GB9825632D0 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2000030679A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003295471B2 (en) | 2002-11-15 | 2011-08-25 | Genmab A/S | Human monoclonal antibodies against CD25 |
| US8252126B2 (en) * | 2004-05-06 | 2012-08-28 | Global Advanced Metals, Usa, Inc. | Sputter targets and methods of forming same by rotary axial forging |
| CA3045944A1 (en) | 2016-12-07 | 2018-06-14 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| CA3054632A1 (en) | 2017-03-30 | 2018-10-04 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| US12227565B2 (en) | 2018-06-20 | 2025-02-18 | Biora Therapeutics, Inc. | Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine |
| CN113348011B (zh) | 2018-11-19 | 2023-04-18 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3815472A1 (de) * | 1988-05-06 | 1989-11-16 | Centre Regional De Transfusion | Monoklonaler antikoerper und seine verwendung |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| HUT60768A (en) | 1990-03-16 | 1992-10-28 | Sandoz Ag | Process for producing cd25 fixing molecules |
| JPH05244982A (ja) * | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| US5428040A (en) * | 1993-08-31 | 1995-06-27 | The Du Pont Merck Pharmaceutical Company | Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents |
| DE69736750T2 (de) * | 1996-07-30 | 2007-08-16 | Novartis Ag | Pharmazeutische zusammensetzungen zur behandlung der transplantatabstossung sowie der autoimmun- oder entzündlichen zustände |
| US6013256A (en) * | 1996-09-24 | 2000-01-11 | Protein Design Labs, Inc. | Method of preventing acute rejection following solid organ transplantation |
-
1998
- 1998-11-23 GB GBGB9825632.4A patent/GB9825632D0/en not_active Ceased
-
1999
- 1999-11-22 AU AU13846/00A patent/AU1384600A/en not_active Abandoned
- 1999-11-22 JP JP2000583562A patent/JP2002530354A/ja active Pending
- 1999-11-22 EP EP99972545A patent/EP1131098A1/en not_active Withdrawn
- 1999-11-22 WO PCT/EP1999/008988 patent/WO2000030679A1/en not_active Ceased
-
2001
- 2001-05-22 US US09/862,212 patent/US20010041179A1/en not_active Abandoned
-
2008
- 2008-07-28 US US12/180,660 patent/US20080286281A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nashan | Review of the proliferation inhibitor everolimus | |
| US9486445B2 (en) | Combination therapy for proliferative disorders | |
| Hernández et al. | Reduction of severe gingival overgrowth in a kidney transplant patient by replacing cyclosporin A with tacrolimus | |
| JPH0373158A (ja) | 哺乳動物に対する臓器又は組織の移植の拒絶を禁止する組成物 | |
| AU2007204963A1 (en) | Viral hepatitis treatment | |
| US20080286281A1 (en) | Cd25 binding molecules for the use in the treatment of manifestations of rejection in transplantation | |
| Kahan | Sirolimus-based immunosuppression: present state of the art | |
| US20110142953A1 (en) | Combinations of immunosuppressive agents for the treatment or prevention of graft rejections | |
| JP2008520682A (ja) | ヒストンデアセチラーゼ阻害剤およびその使用方法 | |
| US20120329779A1 (en) | Method of Treating Mixed Lineage Leukemia Gene-Rearranged Acute Lymphoblastic Leukemias | |
| CN100479814C (zh) | 促淋巴细胞归巢剂在制备用于治疗移植物功能恢复延迟的药物中的用途 | |
| CN112512516A (zh) | 用于在已经经历造血干细胞移植的患者中抑制血液恶性肿瘤复发的活性剂 | |
| JP6878418B2 (ja) | 移植片拒絶反応の処置方法 | |
| WO2000038694A1 (en) | Medicinal compositions for treating osseous lesion in multiple myeloma | |
| AU2006247473A1 (en) | The use of rapamycin derivatives for the treatment and/or prevention of cardiovascular disorders | |
| CN112773802A (zh) | 一种化合物用于预防或治疗移植物抗宿主病的用途 | |
| GB2185886A (en) | Immunosuppressant agents containing ergot derivatives | |
| EP0372541A1 (en) | Method for imparting immunosuppression | |
| JP2006527232A (ja) | グルタミナーゼ及び抗新生物性のアントラサイクリン類又は白金化合物を含有する癌治療のための薬剤学的な組合せ製剤 | |
| Abrams et al. | Role of tacrolimus prolonged release in the prevention of allograft rejection | |
| WO2020160813A1 (en) | Method of treatment and pharmaceutical dosage form | |
| CN118178371A (zh) | 二甲双胍联合核苷酸衍生物在制备治疗口腔鳞癌的药物中的用途 | |
| Becker et al. | Improved renal function of an everolimus/enteric-coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 2 years follow-up of the Zeus Trial: 1757 | |
| CN117224519A (zh) | L-犬尿氨酸作为一种免疫调节剂在器官移植中的应用 |